Dr. Kai Wang has extensive clinical experience in pediatric hematology and oncology. He specializes in the standardized diagnosis and multidisciplinary management of pediatric acute and chronic leukemia, lymphoma, solid tumors, and various rare hematologic disorders. He has substantial expertise in hematopoietic stem cell transplantation and cellular immunotherapy—including both donor-derived and autologous CAR-T treatments—and is particularly experienced in treating refractory and relapsed pediatric hematologic malignancies.
Dr. Wang was among the first in China to explore donor-derived CAR-T therapy for post-transplant relapsed pediatric leukemia and has actively advanced early-phase CAR-T research in pediatric solid tumors. His work has been selected for oral presentations at major international conferences such as ASH (American Society of Hematology). He has published multiple first-author papers, contributed to several pediatric hematology/oncology monographs, and led provincial-level research projects. With deep involvement in integrated diagnostics, treatment strategy development, and cutting-edge immunotherapy, Dr. Wang is recognized as a key young expert in precision therapy for pediatric hematologic malignancies in China.
